|
|||||
|
|
Effect of rifampin on the pharmacokinetics,safety and tolerability of navitoclax (ABT‐263), a dual inhibitor of Bcl‐2 and Bcl‐XL,in patients with cancer |
|
| Authors: | J. Yang R. S. Pradhan L. S. Rosen A. M. Graham K. D. Holen H. Xiong |
| Affiliation: | 1. AbbVie Inc., , North Chicago, IL, USA;2. Alexion Pharmaceuticals, Inc., , Cheshire, CT, USA;3. UCLA Santa Monica Hematology‐Oncology, , Santa Monica, CA, USA |
| Abstract: | |
| Keywords: | Bcl‐2 inhibitor CYP3A inducer drug interaction navitoclax pharmacokinetics rifampin |